Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Obesity01:24

Obesity

1.6K
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

351
In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
351
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

425
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
425
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

310
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
310
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

2
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
2
Diabetes: Symptoms, Diagnosis, and Complications01:15

Diabetes: Symptoms, Diagnosis, and Complications

2.9K
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Effects of Incretin Mimetic Therapies on Muscle and Bone Health in Older Adults: A Narrative Review.

Obesity (Silver Spring, Md.)·2026
Same author

Eating behaviours, prevalence of obesity & health policies.

International journal of food sciences and nutrition·2026
Same author

Association of Testosterone With Lean Soft Tissue and Handgrip Strength Across Middle-Aged Men.

Journal of cachexia, sarcopenia and muscle·2026
Same author

Allostatic Load in Endometrial Cancer Disparities.

medRxiv : the preprint server for health sciences·2026
Same author

Sarcopenic obesity and dementia risk: Primary associations and landmark analyses of muscle strength and body composition trajectories.

Clinical nutrition (Edinburgh, Scotland)·2026
Same author

Contribution of Obesity to Polypharmacy in U.S. Older Adults.

Journal of general internal medicine·2026

Related Experiment Video

Updated: Apr 20, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K

Obesity is always a clinically relevant chronic disease.

Lorenzo M Donini1, Maria D Ballesteros-Pomar2, John A Batsis3

  • 1Department of Experimental Medicine, Sapienza University, Rome, Italy. lorenzomaria.donini@uniroma1.it.

Eating and Weight Disorders : EWD
|April 18, 2026
PubMed
Summary

Obesity management is evolving with new drugs, prompting discussions on recognizing obesity as a disease and refining diagnostic criteria. This analysis compares key statements on obesity diagnosis and treatment timing.

Keywords:
Bio-psycho-social modelChronic diseaseObesityObesity medication

More Related Videos

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.5K
Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas
03:07

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas

Published on: November 11, 2025

556

Related Experiment Videos

Last Updated: Apr 20, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

1.5K
A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats
06:28

A Chronic High-Intensity Interval Training and Diet-Induced Obesity Model to Maximize Exercise Effort and Induce Physiologic Changes in Rats

Published on: April 28, 2023

1.5K
Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas
03:07

Development and Validation of a Methodology for Establishing Obese Rat Models with Typical Fatty Pancreas

Published on: November 11, 2025

556

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Public Health

Background:

  • Recent advancements in pharmacological treatments have increased interest in obesity.
  • This has led to debates regarding obesity's disease status and diagnostic criteria.

Purpose of the Study:

  • To critically analyze statements from the European Association for the Study of Obesity (EASO) and the Lancet Diabetes Endocrinology Commission.
  • To discuss discrepancies and potential misunderstandings in obesity diagnosis and treatment guidelines.

Main Methods:

  • Comparative analysis of EASO and Lancet Diabetes Endocrinology Commission statements.
  • Discussion of Body Mass Index (BMI) limitations and the role of body composition.
  • Examination of obesity as a chronic disease considering biological, psychological, and social factors.

Main Results:

  • Current BMI metrics for obesity diagnosis have limitations.
  • Visceral fat and body composition assessment are crucial for accurate obesity diagnosis.
  • Obesity should be consistently viewed as a clinically relevant chronic disease.

Conclusions:

  • Revising obesity diagnostic criteria beyond BMI is necessary.
  • Integrating body composition analysis will improve patient stratification and treatment.
  • Acknowledging obesity as a chronic disease is vital for comprehensive management and patient care.